ACRO Biomedical, a company located in the Kaohsiung Science Park and is attracting cooperation from the United States, Japan and Australia with regenerative medicine, has recently completed the public issuance procedures and officially entered the domestic investment market with stock code 6748.

CEO Dr. Dar-Jen Hsieh stated,"Biomedical is an industry which combines capital, technology, time and manpower. We believe that persistence is the key to success, now that we have successfully established a good reputation in the global market with our proprietary technology, more and more international biomedical companies and investment teams are interested in cross-border cooperation.”

ACRO Biomedical's initial public offering (6748) not only increases visibility of the company in the investment market, but also gives people a glimpse into the current and future development of regenerative medicine. Please contact us at (07)695-5569